NASDAQ Framework: Immunovant Inc.

Clinical-stage biopharmaceutical company developing autoimmune treatments 1 2 3.

Immunovant, Inc., based in New York, New York, is a clinical-stage biopharmaceutical company focused on developing innovative treatments for autoimmune diseases 4 5 6. As a subsidiary of Roivant Sciences Ltd., Immunovant is a trailblazer in anti-FcRn technology, developing targeted therapies such as batoclimab and IMVT-1402, which are novel, fully human monoclonal antibodies aimed at reducing harmful immunoglobulin G (IgG) autoantibodies 7 8 9. The company is dedicated to enabling normal lives for patients with autoimmune diseases through its patient-focused approach and promising clinical trials 10 11.

4: Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. View Source5: Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. View Source6: Immunovant, Inc. 320 W 37th Street 6th Floor New York, NY 10018 View Source7: Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. View Source8: Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease.... View Source9: Immunovant’s two investigational products, IMVT-1402 and batoclimab, are novel, fully human, monoclonal antibodies that target FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of autoimmune disease. We believe that both product candidates have the potential to address a variety of IgG-mediated autoimmune diseases as subcutaneous injections with dosing that may be tailored, based on disease stage and severity. View Source10: Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. View Source11: At Immunovant, we are applying a patient-focused approach to help advance treatments for these individuals. View Source

UNKNOWN

The provided facts do not contain information about whether Immunovant Inc. is still led by its founders or if the founders are heavily involved.

MEDIUM RISK

Immunovant Inc. is a clinical-stage biopharmaceutical company, which means it is not yet generating revenue from product sales and relies on funding for its operations. While the company has promising clinical trials and innovative therapies in development, it has also faced challenges such as missed earnings and delays in its pipeline 12 13 14 15. Additionally, insider trading activities by key executives may indicate potential concerns about the company's short-term performance 16 17. These factors suggest that while Immunovant has potential, it also faces significant financial risks typical of clinical-stage companies.

12: Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus View Source13: Immunovant changes up plans for closely watched autoimmune drugs View Source14: Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound? View Source15: After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay View Source16: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 57.68 percent of Immunovant Inc shares are owned by insiders, and 47.34 percent are held by financial institutions. Salzmann Peter, the Chief Executive Officer at Immunovant Inc (IMVT) has sold 8,685 shares of firm on Jul 17 ’24 at a price of $29.69 against the total amount of $0.26 million. In another inside trade, Barnett Eva Renee, Chief Financial Officer of Immunovant Inc (NASDAQ:IMVT) sold 3,123 shares of the firm on Jul 17 ’24 for a total worth of $92733.0 at a price of $29.69. An inside trade which took place on Jul 17 ’24, Chief Medical Officer of Immunovant Inc Macias William L. sold 3,044 shares of firm against total price of $90386.0 at the cost of $29.69 per share. View Source17: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 57.19 percent of Immunovant Inc shares are owned by insiders, and 47.17 percent are held by financial institutions. Salzmann Peter, the Chief Executive Officer at Immunovant Inc (IMVT) has sold 16,163 shares of firm on May 22 ’24 at a price of $29.65 against the total amount of $0.48 million. In another inside trade, Barnett Eva Renee, Chief Financial Officer of Immunovant Inc (NASDAQ:IMVT) sold 4,042 shares of the firm on May 22 ’24 for a total worth of $0.12 million at a price of $29.65. An inside trade which took place on May 22 ’24, Chief Development Officer of Immunovant Inc Butchko Julia G. sold 3,247 shares of firm against total price of $96274.0 at the cost of $29.65 per share. View Source

YES

Immunovant Inc. is developing new product offerings, specifically batoclimab and IMVT-1402, which are novel, fully human monoclonal antibodies aimed at reducing harmful immunoglobulin G (IgG) autoantibodies 18 19.

18: Immunovant’s two investigational products, IMVT-1402 and batoclimab, are novel, fully human, monoclonal antibodies that target FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of autoimmune disease. We believe that both product candidates have the potential to address a variety of IgG-mediated autoimmune diseases as subcutaneous injections with dosing that may be tailored, based on disease stage and severity. View Source19: Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). View Source

Immunovant Inc.'s product roadmap for 2024 through 2026 focuses on advancing its two investigational products, batoclimab and IMVT-1402, which are novel, fully human monoclonal antibodies targeting the neonatal fragment crystallizable receptor (FcRn) to reduce harmful immunoglobulin G (IgG) autoantibodies. These therapies are designed to address a variety of IgG-mediated autoimmune diseases with tailored dosing based on disease stage and severity 20 21. The company is committed to leveraging its anti-FcRn technology to develop innovative, targeted treatments that enable normal lives for people with autoimmune diseases 22 23.

20: Immunovant’s two investigational products, IMVT-1402 and batoclimab, are novel, fully human, monoclonal antibodies that target FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of autoimmune disease. We believe that both product candidates have the potential to address a variety of IgG-mediated autoimmune diseases as subcutaneous injections with dosing that may be tailored, based on disease stage and severity. View Source21: Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). View Source22: Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. View Source23: Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease.... View Source

Sources

1: Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. View Source2: Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. View Source3: Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). View Source4: Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. View Source5: Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. View Source6: Immunovant, Inc. 320 W 37th Street 6th Floor New York, NY 10018 View Source7: Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. View Source8: Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease.... View Source9: Immunovant’s two investigational products, IMVT-1402 and batoclimab, are novel, fully human, monoclonal antibodies that target FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of autoimmune disease. We believe that both product candidates have the potential to address a variety of IgG-mediated autoimmune diseases as subcutaneous injections with dosing that may be tailored, based on disease stage and severity. View Source10: Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. View Source11: At Immunovant, we are applying a patient-focused approach to help advance treatments for these individuals. View Source12: Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus View Source13: Immunovant changes up plans for closely watched autoimmune drugs View Source14: Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound? View Source15: After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay View Source16: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 57.68 percent of Immunovant Inc shares are owned by insiders, and 47.34 percent are held by financial institutions. Salzmann Peter, the Chief Executive Officer at Immunovant Inc (IMVT) has sold 8,685 shares of firm on Jul 17 ’24 at a price of $29.69 against the total amount of $0.26 million. In another inside trade, Barnett Eva Renee, Chief Financial Officer of Immunovant Inc (NASDAQ:IMVT) sold 3,123 shares of the firm on Jul 17 ’24 for a total worth of $92733.0 at a price of $29.69. An inside trade which took place on Jul 17 ’24, Chief Medical Officer of Immunovant Inc Macias William L. sold 3,044 shares of firm against total price of $90386.0 at the cost of $29.69 per share. View Source17: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 57.19 percent of Immunovant Inc shares are owned by insiders, and 47.17 percent are held by financial institutions. Salzmann Peter, the Chief Executive Officer at Immunovant Inc (IMVT) has sold 16,163 shares of firm on May 22 ’24 at a price of $29.65 against the total amount of $0.48 million. In another inside trade, Barnett Eva Renee, Chief Financial Officer of Immunovant Inc (NASDAQ:IMVT) sold 4,042 shares of the firm on May 22 ’24 for a total worth of $0.12 million at a price of $29.65. An inside trade which took place on May 22 ’24, Chief Development Officer of Immunovant Inc Butchko Julia G. sold 3,247 shares of firm against total price of $96274.0 at the cost of $29.65 per share. View Source18: Immunovant’s two investigational products, IMVT-1402 and batoclimab, are novel, fully human, monoclonal antibodies that target FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of autoimmune disease. We believe that both product candidates have the potential to address a variety of IgG-mediated autoimmune diseases as subcutaneous injections with dosing that may be tailored, based on disease stage and severity. View Source19: Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). View Source20: Immunovant’s two investigational products, IMVT-1402 and batoclimab, are novel, fully human, monoclonal antibodies that target FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of autoimmune disease. We believe that both product candidates have the potential to address a variety of IgG-mediated autoimmune diseases as subcutaneous injections with dosing that may be tailored, based on disease stage and severity. View Source21: Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). View Source22: Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. View Source23: Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease.... View Source